BR112014023795B1 - Uso de inibidores de ccr3 - Google Patents

Uso de inibidores de ccr3 Download PDF

Info

Publication number
BR112014023795B1
BR112014023795B1 BR112014023795-6A BR112014023795A BR112014023795B1 BR 112014023795 B1 BR112014023795 B1 BR 112014023795B1 BR 112014023795 A BR112014023795 A BR 112014023795A BR 112014023795 B1 BR112014023795 B1 BR 112014023795B1
Authority
BR
Brazil
Prior art keywords
eosinophilic
alkyl
formula
treatment
chloride
Prior art date
Application number
BR112014023795-6A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014023795A8 (pt
BR112014023795A2 (https=
Inventor
Michael Chadham Nivens
Thierry Bouyssou
Rolf Goeggel
Peter Seither
Original Assignee
Alkahest, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014023795(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkahest, Inc. filed Critical Alkahest, Inc.
Publication of BR112014023795A2 publication Critical patent/BR112014023795A2/pt
Publication of BR112014023795A8 publication Critical patent/BR112014023795A8/pt
Publication of BR112014023795B1 publication Critical patent/BR112014023795B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Structure Of Transmissions (AREA)
BR112014023795-6A 2012-04-03 2013-04-02 Uso de inibidores de ccr3 BR112014023795B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12162937.2 2012-04-03
EP12162937 2012-04-03
PCT/EP2013/056864 WO2013149986A1 (en) 2012-04-03 2013-04-02 Use of ccr3-inhibitors

Publications (3)

Publication Number Publication Date
BR112014023795A2 BR112014023795A2 (https=) 2017-06-20
BR112014023795A8 BR112014023795A8 (pt) 2017-10-10
BR112014023795B1 true BR112014023795B1 (pt) 2021-09-08

Family

ID=48040249

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014023795-6A BR112014023795B1 (pt) 2012-04-03 2013-04-02 Uso de inibidores de ccr3

Country Status (28)

Country Link
US (5) US20130261153A1 (https=)
EP (3) EP4389217A3 (https=)
JP (2) JP2015512432A (https=)
KR (5) KR20220132012A (https=)
CN (2) CN104220073A (https=)
AU (1) AU2013245027B2 (https=)
BR (1) BR112014023795B1 (https=)
CA (1) CA2869269C (https=)
CL (1) CL2014002523A1 (https=)
CY (1) CY1123222T1 (https=)
DK (1) DK2833884T3 (https=)
EA (1) EA032263B1 (https=)
ES (2) ES2987267T3 (https=)
HR (1) HRP20201165T1 (https=)
HU (1) HUE051648T2 (https=)
IL (1) IL234262A (https=)
IN (1) IN2014DN06989A (https=)
LT (1) LT2833884T (https=)
MX (1) MX2014011786A (https=)
NZ (1) NZ628882A (https=)
PH (1) PH12014502239A1 (https=)
PL (1) PL2833884T3 (https=)
PT (1) PT2833884T (https=)
RS (1) RS60665B1 (https=)
SI (1) SI2833884T1 (https=)
SM (1) SMT202000499T1 (https=)
WO (1) WO2013149986A1 (https=)
ZA (1) ZA201406082B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
EP3449866B1 (en) 2016-11-24 2021-10-20 Kirishima Seiko Co., Ltd. Orthodontic appliance
CN110636844A (zh) * 2017-04-05 2019-12-31 万能溶剂有限公司 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物
MY199462A (en) * 2017-04-05 2023-10-30 Alkahest Inc Methods and compositions for treating retina-associated disease using ccr3-inhibitors
CN111343983A (zh) * 2017-10-13 2020-06-26 万能溶剂有限公司 使用ccr3抑制剂治疗瘙痒、干燥症和相关疾病的方法和组合物
MY198220A (en) 2018-05-15 2023-08-14 Alkahest Inc Treatment Of Aging-Associated Disease With Modulators Of Leukotriene A4 Hydrolase
KR20210065950A (ko) * 2018-09-26 2021-06-04 알카헤스트 인코포레이티드 Ccr3-억제제를 사용한 노화 관련 장애 치료를 위한 방법 및 조성물
US20230312697A1 (en) * 2020-06-11 2023-10-05 Alkahest Inc. Methods of improving retina-associated disease outcome using ccr3-inhibitors
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
ATE414151T1 (de) * 2000-03-03 2008-11-15 Cambridge Antibody Tech Antikörper gegen eotaxin und deren verwendung
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
US8030003B2 (en) * 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
US8008092B2 (en) * 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
WO2010138591A1 (en) * 2009-05-26 2010-12-02 University Of Kentucky Research Foundation Ccr3 and its ligands are therapeutic and diagnostic targets for neovascular age-related macular degeneration
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Also Published As

Publication number Publication date
EP3763369A1 (en) 2021-01-13
SI2833884T1 (sl) 2020-10-30
HRP20201165T1 (hr) 2020-12-11
WO2013149986A1 (en) 2013-10-10
EP2833884B1 (en) 2020-05-20
KR20220132012A (ko) 2022-09-29
EP4389217A2 (en) 2024-06-26
RS60665B1 (sr) 2020-09-30
KR20210063481A (ko) 2021-06-01
ZA201406082B (en) 2019-01-30
HUE051648T2 (hu) 2021-03-29
PT2833884T (pt) 2020-08-26
US20160081998A1 (en) 2016-03-24
KR20140144200A (ko) 2014-12-18
DK2833884T3 (da) 2020-08-10
IL234262A (en) 2017-10-31
JP2018080183A (ja) 2018-05-24
EP2833884A1 (en) 2015-02-11
JP2015512432A (ja) 2015-04-27
NZ628882A (en) 2016-05-27
US20170319567A1 (en) 2017-11-09
MX2014011786A (es) 2014-12-05
EA032263B1 (ru) 2019-05-31
KR20250133980A (ko) 2025-09-09
BR112014023795A8 (pt) 2017-10-10
CL2014002523A1 (es) 2015-01-23
AU2013245027A1 (en) 2014-09-11
KR20200044988A (ko) 2020-04-29
PL2833884T3 (pl) 2020-11-02
US20150099783A1 (en) 2015-04-09
US20200375971A1 (en) 2020-12-03
EP4389217A3 (en) 2024-08-28
PH12014502239A1 (en) 2014-12-15
ES2987267T3 (es) 2024-11-14
IN2014DN06989A (https=) 2015-04-10
LT2833884T (lt) 2020-09-10
BR112014023795A2 (https=) 2017-06-20
US20130261153A1 (en) 2013-10-03
CN104220073A (zh) 2014-12-17
CY1123222T1 (el) 2021-10-29
CA2869269A1 (en) 2013-10-10
SMT202000499T1 (it) 2020-11-10
EP3763369B1 (en) 2024-02-28
ES2811554T3 (es) 2021-03-12
AU2013245027B2 (en) 2017-10-12
CN110384699A (zh) 2019-10-29
EA201401083A1 (ru) 2015-03-31
CA2869269C (en) 2020-06-30

Similar Documents

Publication Publication Date Title
BR112014023795B1 (pt) Uso de inibidores de ccr3
JP6700332B2 (ja) Ｃｃｒ３アンタゴニストを含む医薬製剤
RU2406499C2 (ru) Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений
JP2020525480A (ja) 純粋な５−ｈｔ６受容体アンタゴニストの新たな使用
JP6509244B2 (ja) 水晶体硬化抑制剤
HK40015701A (en) Use of ccr3-inhibitors
WO2016006621A1 (ja) Ｐｇｄ２拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬
CN105934245B (zh) 多发性硬化症的治疗剂或预防剂
CN105497021A (zh) 胺类化合物治疗焦虑障碍的医药用途
JP2010111667A (ja) フェキソフェナジン又はエバスチンを含有する鎮咳及び／又は去痰のための医薬組成物
CN1897952B (zh) 中性白细胞增多抑制剂
WO2013131324A1 (zh) 卢帕他定在制备治疗慢性阻塞性肺病药物组合物中的应用
JPS62209019A (ja) 抗潰瘍剤
EA042685B1 (ru) Новые применения чистого антагониста 5-ht6 рецептора

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ALKAHEST, INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/04/2013, OBSERVADAS AS CONDICOES LEGAIS.